Managed Entry Agreement

How a managed entry agreement supports access under uncertainty

A managed entry agreement sets additional conditions for the coverage, pricing, payment or use of a health technology when decision makers are not prepared to provide unrestricted access on ordinary terms. This page explains why these agreements are used, how different arrangements allocate financial and evidential risk, and what is required for an agreement to produce useful evidence or affordable access.

The agreement sits between a payer and a manufacturer or another technology supplier, although providers, clinicians, data holders and patients may also have important roles. Its value depends on whether the arrangement addresses a clearly identified decision problem rather than merely delaying a difficult reimbursement decision.

Why managed entry agreements are used

Decision makers may face pressure to provide timely access while important uncertainty remains about effectiveness, safety, cost effectiveness, budget impact or use in routine practice. A managed entry agreement can make access conditional on financial terms, restrictions, evidence collection or future review.

Common objectives include:

• Reducing the effective price or financial exposure faced by the payer.
• Limiting use to patients most likely to benefit.
• Linking payment to observed outcomes or treatment performance.
• Generating evidence that can resolve an important uncertainty.
• Managing high or unpredictable budget impact.
• Allowing temporary access while a future reimbursement decision is prepared.
• Sharing some of the risk associated with uncertain value between the payer and supplier.

These objectives should be stated separately. An agreement that controls expenditure may not generate useful evidence, and an agreement that collects data may not make the technology affordable.

The main types of agreement

Managed entry agreements can be classified according to whether their central mechanism is financial, performance based or evidence generating. Real agreements may combine more than one mechanism.

Financial agreements

Financial agreements alter the price paid or limit expenditure without making payment depend directly on individual patient outcomes. They can be relatively straightforward to administer when transactions are observable and the financial rules are clear.

Examples include:

• Simple discounts or rebates.
• Price-volume agreements.
• Expenditure caps.
• Dose or treatment-duration caps.
• Free initiation periods.
• Manufacturer-funded doses or cycles.
• Refunds triggered by spending above an agreed threshold.

These arrangements can improve affordability or cost effectiveness, but confidential terms may make the true price difficult to observe and may reduce transparency across organisations or jurisdictions.

Performance-based agreements

Performance-based agreements link payment, reimbursement or continued coverage to patient outcomes or another measure of technology performance. They are intended to align the amount paid with the value observed in practice.

Examples include:

• Payment only for patients who respond.
• Full or partial refunds for non-response.
• Continuation of treatment only when a clinical target is achieved.
• Payments adjusted according to an agreed outcome measure.
• Population-level payments linked to aggregate performance.

These agreements require an outcome that can be measured consistently within an appropriate timeframe. They become difficult to operate when outcomes are subjective, delayed, affected by many other factors or unavailable in routine data.

Coverage with evidence development

Coverage with evidence development provides conditional or temporary access while additional evidence is collected. The evidence should address uncertainty that is important to the coverage or pricing decision and capable of being reduced within the agreed period.

The arrangement may require:

• Participation in a registry.
• Completion of a clinical study.
• Collection of patient-reported outcomes.
• Longer-term follow-up.
• Comparative effectiveness analysis.
• Collection of resource-use or quality-of-life data.
• A defined reassessment after evidence generation.

Data collection alone does not establish a successful evidence-development agreement. The study must be designed to answer the uncertainty that prevented an ordinary decision.

Identifying the uncertainty to be managed

The agreement should begin with a specific account of what is uncertain and why that uncertainty matters. A broad statement that more evidence is needed is insufficient for designing data collection or a future reassessment.

Material uncertainties may concern:

• The size or durability of the treatment effect.
• Effectiveness in routine clinical practice.
• Long-term safety.
• The population most likely to benefit.
• Treatment duration, adherence or discontinuation.
• Health-related quality of life.
• Resource use and downstream costs.
• The number of eligible patients.
• Uptake and displacement of existing treatments.
• The transferability of evidence to the decision setting.

An evidence-generating agreement is most appropriate when the uncertainty can be reduced through feasible research. It is less useful when the necessary evidence would take too long, the relevant outcome cannot be measured reliably or the decision would remain unchanged under every plausible result.

Designing the agreement

A managed entry agreement needs operational rules that translate its objective into coverage, payment and evidence requirements. Ambiguous terms create disputes and can make the final data impossible to interpret.

The design should specify:

1. Define the eligible population using criteria that can be applied consistently in practice.
2. Identify the participating organisations and assign responsibility for prescribing, data collection, payment and oversight.
3. Specify the financial mechanism including the price, discount, cap, refund or payment-adjustment rule.
4. Define the relevant outcomes and how, when and by whom they will be measured.
5. Set the evidence plan around the uncertainty that the future decision must resolve.
6. Establish the duration of the agreement and any interim review points.
7. State the reassessment criteria and the possible decisions after review.
8. Define termination and transition arrangements for patients already receiving treatment.
9. Document governance, audit and dispute procedures.

The agreement should be understandable to the people responsible for implementing it. A sophisticated payment formula has little value if providers cannot identify eligible patients or submit the necessary data.

Choosing outcomes for performance-based payment

An outcome-linked agreement requires a measure that is clinically meaningful, measurable in routine practice and attributable enough to support the payment rule. The measurement period should be long enough to observe a relevant effect but short enough for the agreement to operate.

A suitable outcome should have:

• A clear definition.
• An agreed baseline.
• A reliable data source.
• A specified assessment time.
• Rules for missing or ambiguous results.
• A threshold that has clinical and contractual meaning.
• Procedures for verification and audit.
• A credible relationship to the value expected from the technology.

Surrogate outcomes may make an agreement easier to administer but may not represent the final health benefit. If a surrogate is used, the remaining uncertainty about its relationship to patient-relevant outcomes should be explicit.

Allocating financial risk

Financial arrangements determine which party bears the cost when uptake, treatment duration or performance differs from expectation. The risk should be assigned to the party best able to influence, measure or absorb it without creating harmful incentives.

For a simple outcome-based refund, the payer's net treatment cost may be represented as:

$$ Net\ cost = Gross\ treatment\ cost - Refunds $$

If a proportion (p_{NR}) of treated patients meet the agreed definition of non-response and the refund per non-responder is (R), expected refunds for (N) treated patients are:

$$ Expected\ refunds = N \times p_{NR} \times R $$

The calculation is operationally useful only when treatment records, response status and refund rules are complete and auditable. Administrative costs should also be included when assessing the value of the agreement.

Evidence generation and reassessment

An evidence-development agreement should connect each important uncertainty to a research question, data source and analytical method. The future reassessment should be planned before the new results are known.

The evidence plan should describe:

• The target population and comparator.
• The outcomes and follow-up period.
• The data source and expected sample size.
• The study design and analytical methods.
• The approach to confounding, missing data and treatment changes.
• The expected precision and limitations.
• The timetable for analysis and reporting.
• The party responsible for analysis.
• Independent oversight or validation.
• How the results will affect price, coverage or use.

A registry may support the plan, but establishing a registry does not guarantee that the data will answer a comparative or causal question. Evidence requirements should be proportionate to the uncertainty and capable of supporting the intended reassessment.

Data and implementation requirements

Managed entry agreements can impose substantial administrative burden on clinicians, providers, payers and patients. A design that appears attractive in principle may fail when the required data are unavailable or payment systems cannot apply the contractual rules.

Implementation should address:

• Patient identification and eligibility verification.
• Consent and lawful data use.
• Data ownership, access and retention.
• Interoperability between clinical and payment systems.
• Data completeness and timeliness.
• Validation of outcome and payment records.
• Procedures for correcting errors.
• Staffing and training.
• Administrative and analytical costs.
• Protection of confidential commercial information.

The burden of data collection should be justified by the value of the uncertainty it can resolve. Collecting extensive data without a clear analytical purpose wastes resources and may reduce clinical participation.

Economic evaluation of the agreement

The technology and the managed entry agreement should not be treated as the same intervention. The agreement changes the effective price, implementation costs, evidence available and possibly the population or conditions of use.

An economic evaluation may need to consider:

• The net price after discounts, rebates or refunds.
• Administrative and data-collection costs.
• Changes in uptake and eligible population.
• Effects of treatment stopping rules.
• Delays in access or reimbursement.
• The value of reducing decision uncertainty.
• Financial risk transferred between parties.
• Future consequences of reassessment.
• Opportunity costs created by temporary coverage.

An agreement can improve the expected cost effectiveness of a technology while still producing unaffordable budget impact. Cost effectiveness and affordability should therefore be evaluated separately.

Governance and transparency

Governance should protect the integrity of evidence, payment calculations and future decisions. Roles and conflicts of interest should be declared, and analytical independence should be preserved when the supplier funds data collection or analysis.

Confidentiality may protect commercially sensitive terms, but excessive secrecy can limit public accountability, comparison between technologies and assessment of whether promised evidence was produced. Decision makers should distinguish information that genuinely requires protection from information needed to understand the basis of coverage.

Patients should be informed when access depends on data collection or outcome-linked rules. The agreement should also address what happens to ongoing treatment if coverage changes after reassessment.

A simplified example

Suppose a new medicine has promising short-term trial results, but its long-term benefit and duration of treatment are uncertain. The payer provides temporary coverage for eligible patients while a registry collects response, discontinuation, quality-of-life and resource-use data for three years.

The manufacturer provides a refund for patients who do not meet a prespecified response criterion at six months. At the end of three years, the technology is reassessed using the new evidence and the effective price after refunds.

This arrangement contains both a performance-based financial component and coverage with evidence development. Its success depends on whether the six-month response measure is meaningful, registry data are sufficiently complete, and the reassessment rules specify how different findings will affect future coverage.

When an agreement may not be appropriate

A managed entry agreement should not be used merely because a technology is expensive or evidence is uncertain. Ordinary price negotiation, restricted coverage, additional research or rejection may be more appropriate.

An agreement may offer limited value when:

• The uncertainty cannot be reduced within a useful timeframe.
• The required outcome cannot be measured reliably.
• The administrative cost is disproportionate to the expected benefit.
• The eligible population is too small for informative evidence generation.
• The agreement duplicates data already being collected.
• The future decision is unlikely to change regardless of the evidence.
• The financial mechanism creates incentives that could harm patients.
• Responsibilities and reassessment consequences cannot be agreed.

The option of not entering an agreement should remain explicit. Conditional access is not automatically preferable to a clear coverage or non-coverage decision.

Common misunderstandings

Managed entry agreement is an umbrella term rather than a single payment method. Agreements differ in their objectives, financial mechanisms, evidence requirements and legal form.

Common misunderstandings include:

• A confidential discount is not automatically an outcomes-based agreement.
• Collecting routine data does not automatically reduce uncertainty.
• A performance-based agreement does not eliminate confounding or measurement error.
• Temporary access does not guarantee permanent reimbursement.
• A lower effective price does not automatically resolve high budget impact.
• An agreement does not remove the need for an initial assessment of benefits, harms and value.
• Risk is not necessarily shared fairly merely because the arrangement is called risk sharing.
• Complex contracts are not necessarily more effective than simple financial terms.

Interpreting the value of a managed entry agreement

The success of an agreement should be judged against its stated objective. A financial agreement may succeed by controlling expenditure, while an evidence-development agreement should produce evidence capable of informing a future decision.

A useful managed entry agreement has clear rules, manageable administration, credible data and a defined exit or reassessment pathway. It should improve the decision or its implementation rather than obscure the true price, postpone uncertainty or create an evidence system with no practical consequence.